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Abstract Objective: Pulmonary
hypertension is a characteristic
feature of acute respiratory distress
syndrome (ARDS) and contributes to
mortality. Administration of sildenafil
in ambulatory patients with pulmon-
ary hypertension improves
oxygenation and ameliorates pul-
monary hypertension. Our aim was to
determine whether sildenafil is bene-
ficial for patients with ARDS.
Design: Prospective, open-label,
multicenter, interventional cohort
study. Setting: Medical-surgical
ICU of two university hospitals.
Patients: Ten consecutive patients
meeting the NAECC criteria for
ARDS. Interventions: A single dose
of 50 mg sildenafil citrate adminis-
tered via a nasogastric tube. Main
results: Administration of sildenafil
in patients with ARDS decreased
mean pulmonary arterial pressure
from 25 to 22 mmHg (P = 0.022)
and pulmonary artery occlusion
pressure from 16 to 13 mmHg
(P = 0.049). Systemic mean arterial
pressures were markedly decreased
from 81 to 75 mmHg (P = 0.005).
Sildenafil did not improve pulmonary
arterial oxygen tension, but resulted
in a further increase in the shunt
fraction.
Conclusion: Although sildenafil
reduced pulmonary arterial pressures
during ARDS, the increased shunt
fraction and decreased arterial oxy-
genation render it unsuitable for the
treatment of patients with ARDS.
Keywords Sildenafil  ARDS 
Hypoxemia  Pulmonary
hypertension  ICU
Introduction
With an incidence of 24 per 100,000 in The Netherlands,
acute respiratory distress syndrome (ARDS) is a common
cause of respiratory insufficiency requiring mechanical
ventilation and admission to an intensive care unit (ICU)
[1]. Both direct (e.g., pneumonia, inhalation injury) and
indirect lung injury (e.g., sepsis, acute pancreatitis)
can induce ARDS [2], which is characterized by pul-
monary edema (resulting from increased vascular
permeability), atelectasis and a ventilation-perfusion
mismatch. As a result, impaired gas exchange and hyp-
oxemia develop. Due to hypoxia, the pulmonary arteries
constrict, a phenomenon known as hypoxic pulmonary
vasoconstriction [3]. Thrombo-embolic occlusions in the
pulmonary microvasculature [4], increased production of
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vasoconstrictive agents such as endothelin-1 [5] and
thromboxane A2 [6], and pulmonary edema further aug-
ment pulmonary hypertension, which is a hallmark of
ARDS [7]. The presence of pulmonary hypertension
contributes to mortality [8]. Current treatment of ARDS is
supportive. Specific therapeutic strategies are lacking.
Inhalation of nitric oxide (NO) dilates the pulmonary
vasculature and enhances perfusion to ventilated lung
regions, thereby improving oxygenation in patients with
ARDS [9, 10]. However, NO inhalation as an adjunctive
therapy in ARDS is controversial, since a considerable
number of patients are unresponsive, and NO also has
adverse effects, including renal dysfunction [11, 12].
Impaired vasoreactivity is likely to explain unrespon-
siveness to inhaled NO. Under physiological conditions,
NO initiates the conversion of guanosine triphosphate
(GTP) to cyclic guanosine monophosphate (cGMP) in
pulmonary endothelial cells. Activation of cGMP-depen-
dent protein kinases induces relaxation of smooth muscle
cells and thus vasodilation. A family of enzymes called
phosphodiesterases (PDE) inactivates cGMP by convert-
ing it to GMP [13]. During sepsis, pulmonary cGMP
release may be impaired, as suggested in an animal model
of endotoxemia, thereby accounting for the pulmonary
vasounresponsiveness to NO [14]. Additionally, increased
PDE activity may contribute to enhanced degradation of
cGMP [15, 16]. Inhibition of PDE may therefore improve
or even replace inhalational NO therapy in ARDS. In
accordance, previous animal studies have demonstrated
beneficial effects of PDE inhibitors in experimental
ARDS by attenuating endotoxin-induced vasomotor
dysfunction [17–19]. Besides influencing vasoreactivity,
PDE inhibitors also have antiinflammatory properties,
decreasing pulmonary edema, neutrophil infiltration,
reactive oxygen species and levels of proinflammatory
mediators in experimental acute lung injury [17–19].
These preclinical results suggest that inhibiting PDE may
be a potential therapeutic target in ARDS.
Sildenafil selectively inhibits the isoenzyme PDE type
5 (PDE5), which is specific for cGMP [20]. It has been
demonstrated that sildenafil increases exercise capacity
during severe hypoxia in healthy volunteers [21] and
improves gas exchange in patients with pulmonary
hypertension [22] by selectively dilating arteries in well-
ventilated areas of the lung [23]. We hypothesized that
sildenafil administered to patients with ARDS would
improve hypoxemia by regulation of vascular tone,
thereby decreasing the shunt fraction.
Materials and methods
Patients
This prospective, interventional cohort study was
approved by the Ethics Committee of the VU University
Medical Center. Written informed consent was obtained
from the patients’ next of kin. We enrolled ten patients
within 1 week after establishing the diagnosis of ARDS;
they were older than 18 years and admitted to the mixed
medical/surgical ICUs of two university hospitals. ARDS
was diagnosed according to the North American Euro-
pean Consensus Conference (NAECC) definition of
ARDS [24]: partial arterial oxygen tension/fraction of
inspired oxygen (PaO2/FiO2) (P/F) ratio of less than
200 mmHg, bilateral consolidations on a chest X-ray and
the absence of hydrostatic pulmonary edema, which was
defined as a pulmonary artery occlusion pressure (PAOP)
B18 mmHg. In addition, a risk factor associated with
ARDS had to be present. We excluded patients with
coronary artery disease, bilateral pneumonia (patients
with an initial presentation of bilateral infiltrates), pre-
existent lung fibrosis and hepatic insufficiency, as well as
patients who were treated with nitrates, other PDE
inhibitors, prostacyclins or more than 300 mg of hydro-
cortisone (or its equivalent of other steroids) per day.
Bilateral pneumonia and lung fibrosis were exclusion
criteria because of a presumed absence of vasoreactivity.
We also excluded patients in whom nasogastric feeding
(i.e., administration of medication) was not possible
because of an underlying condition.
Study protocol
Demographics, reason for admission to the ICU and
medical history were taken from the chart. To assess
disease severity, the Acute Physiology and Chronic
Health Evaluation (APACHE II) score was calculated
using the worst variables in a 24-h timeframe preceding
enrollment [25]. When not already in place, a pulmonary
artery catheter was inserted. In all patients, central venous
pressure (CVP), pulmonary arterial pressure (PAP) and
cardiac output (CO) were measured by a continuous
cardiac output monitoring balloon-tip thermodilution
pulmonary artery catheter (Baxter Edwards Critical Care,
Irvine, CA) inserted via the internal jugular or subclavian
vein. Pulmonary artery occlusion pressure (PAOP) was
obtained from graphic recordings at end-expiration at the
level of the heart without discontinuation of PEEP. All
pressures were obtained after calibration, zeroing to
atmosphere and using the midchest level as reference.
Arterial blood pressure was continuously monitored with
an intraarterial catheter. Hemodynamic variables were
recorded by a patient data monitoring system.
One tablet of 50 mg of sildenafil was ground and
dissolved in 20 ml of 0.9% NaCl. After baseline mea-
surements (t = 0), the ground sildenafil was administered
as a single dose through the nasogastric tube. Hemody-
namic variables were recorded at t = 30, 60, 90, 120, 150,
180, 210, 240 and 360 min after the sildenafil was
administrated. At the same time points, arterial blood was
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drawn to determine the levels of sildenafil and des-
methylsildenafil. Blood gas analysis of both arterial and
mixed venous blood was performed (Rapid Lab 865,
Bayer Diagnostics, Dublin, Ireland). The shunt fraction
(Qs/Qt) was calculated using a standard formula, Qs=Qt ¼
CcO2  CaO2ð Þ= CcO2  CvO2ð Þ: Ideally, ventilator set-
tings were not changed, and dosages of vasopressors were
not increased unless deemed necessary by the discretion of
the treating physician during the 6 h of monitoring.
Measurements of sildenafil levels
Serum concentrations of sildenafil and its metabolite
desmethylsildenafil were measured using a validated
liquid-gas chromatography mass-spectrometry method
[26]. The calibration curve exhibited a linear range of
0.05–625 ng/ml with a 2-ng/ml limit for detection for
sildenafil and a range of 0.05–280 ng/ml for desmethyl-
sildenafil with a 3-ng/ml detection limit. The intra- and
inter-day precision was within 6% for both compounds.
Intra- and inter-day accuracy ranged from 92–103%.
Statistical analysis
All data are summarized as median (range) or absolute
numbers where appropriate. Measurements were com-
pared to t = 0 using the Wilcoxon signed rank test. The
Spearman correlation coefficient was used to express
relations using baseline and t = 30 min. A P value\0.05
was considered statistically significant. Statistical analysis
was performed using SPSS 14.0 (SPSS, Chicago, IL) and
Prism 5.0 (GraphPad Software, San Diego, CA).
Results
Between 1 December 2005 and 1 December 2007, 21
ARDS patients were assessed for eligibility. Eleven
patients were excluded: three were treated with another
PDE inhibitor (enoximone), three had contraindications to
enteral medications, and one patient suffered from pul-
monary hemorrhage and was excluded for safety reasons.
In three patients, consent was not provided. One patient
was excluded after enrollment because findings on a CT
scan performed on the day after the study protocol had
been carried out rendered him ineligible. The radiological
images indicated atelectasis, not ARDS.
Patient characteristics and baseline hemodynamic and
respiratory parameters are displayed in Table 1. Sepsis
and pneumonia were the most frequent causes of ARDS.
All patients had severe pulmonary injury with pulmonary
hypertension and an increased pulmonary shunt fraction.
The ICU mortality rate was 10%.
Effects on hemodynamic parameters
All hemodynamic effects were most apparent after
30 min. The mean pulmonary arterial pressure (MPAP)
declined after sildenafil from 25 (23–32) mmHg at
baseline to 22 (18–26) mmHg at t = 30 and remained at
this level until t = 180 (P B 0.022) (Fig. 1). The PAOP
decreased from 16 (8–18) mmHg at baseline to 13 (8–18)
mmHg at t = 30 (P = 0.049) and declined further to 12.5
(7–21) mmHg at t = 60 (P = 0.027). Sildenafil induced
vasodilation that was not selective for the pulmonary
vasculature, but decreased the systemic mean arterial
pressure (MAP) from 81 (68–115) to 75 (66–98) mmHg
at t = 30 (P = 0.005) and remained below baseline lev-
els for 3.5 h (Fig. 1). In four of the seven patients
requiring vasopressors, the dose was increased to main-
tain a mean arterial pressure of at least 65 mmHg. This
typically occurred 30–60 min after sildenafil administra-
tion. Sildenafil had a rapid effect on the systemic vascular
resistance index (SVRI), decreasing from 1,688 (1,058–
2,425) dyne*s/cm5 at baseline to 1,400 (917–1,986)
Table 1 Baseline measurements
General n = 10
Age (years) 62.5 (40–78)
Sex (m/f) 7/3
APACHE II 18.5 (9–29)
Cause of ARDS
Sepsis 4
Pneumonia 2
Pleural empyema 1
Post CABG 2
Post open-repair AAA 1
Hemodynamic parameters
Heart rate (/min) 84 (64–108)
MAP (mmHg) 81 (68–115)
CVP (mmHg) 12 (5–15)
MPAP (mmHg) 25 (23–32)
PAOP (mmHg) 16 (8–18)
CO (l/min) 6.85 (4.80–11.70)
CI (l/min*m2) 3.66 (2.68–5.44)
SVRI (dyne*s/cm5) 1,632 (1,058–2,425)
PVRI (dyne*s/cm5) 234 (139–478)
Vasopressors (yes/no) 7/3
Respiratory parameters
PaO2/FiO2 ratio 144 (122–200)
PaO2 (mmHg) 84 (72–103)
PEEP (cmH2O) 10 (8–18)
SvO2 0.65 (0.57–0.72)
A-a gradient (mmHg) 319 (223–362)
Qs/Qt 24 (18–31)
Data are median (range) or absolute numbers: APACHE Acute
Physiology and Chronic Health Evaluation; CABG coronary artery
bypass grafting; AAA abdominal aortic aneurysm; MAP mean
arterial pressure; CVP central venous pressure; MPAP mean pul-
monary artery pressure; PAOP pulmonary artery occlusion
pressure; CO cardiac output; CI cardiac index; SVRI systemic
vascular resistance index; PVRI pulmonary vascular resistance
index; PEEP positive end expiratory pressure; SvO2 mixed venous
saturation; Qs/Qt shunt fraction
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dyne*s/cm5 at t = 30 (P = 0.012). The pulmonary vas-
cular resistance index (PVRI) declined from 215 (139–
478) dyne*s/cm5 at baseline to 170 (71–418) dyne*s/cm5
only after 90 min to remain at this level until t = 210
(P B 0.047). The cardiac index (CI) was 3.4 (2.7–5.4) at
baseline, which did not change over time (at t = 30, CI
was 3.7 (2.6–5.6) and at t = 90: 3.9 (2.1–5.5), NS). The
left ventricular stroke work index was not affected;
however, the right ventricular stroke work index
decreased (P B 0.038). The ratios of PVRI to SVRI and
of MPAP to MAP did not change over time.
Effects on respiratory parameters
Sildenafil administration tended to decrease PaO2 from 87
(72–100) mmHg at baseline to 70 (54–131) mmHg at
t = 30 (P = 0.074), slowly returning to baseline level
after 210 min. The P/F-ratio decreased concordantly from
144 (122–200) at baseline to 115 (77–218) at t = 30
(P = 0.074), returning to baseline at t = 150. The levels
of PEEP and FiO2 were not changed during the obser-
vation period. Simultaneously with the decrement of
PaO2, the shunt fraction increased from 24 (18–31)% to
31 (21–42)% (P B 0.037), returning to baseline at
t = 120 (Fig. 2). The alveolo-arterial (A-a) gradient was
not significantly affected (data not shown). Sildenafil did
not alter levels of PaCO2 (data not shown). There was no
statistically significant correlation between decrease in
shunt fraction and decrease in MAP, nor between
decrease in shunt fraction and decrease in MPAP.
Levels of sildenafil
The maximum plasma concentration (Cmax) of sildenafil
was reached between t = 30 and t = 120, and ranged
from 107 to 975 ng/ml. The Cmax of desmethylsildenafil,
Fig. 1 Boxplot of
hemodynamic variables during
the study period displayed as
median, interquartile range
(box) and range (whiskers). An
asterisk indicates statistically
significant change as compared
to t = 0 (Wilcoxon signed
ranks test)
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the active metabolite of sildenafil, was found to be
between t = 30 and t = 60, and varied between 23 and
191 ng/ml. Correlation coefficients were calculated for
the relation between sildenafil/desmethylsildenafil plasma
concentrations at t = 30 and MPAP, PAOP, MAP and
P/F ratio (Fig. 3, see electronic supplement). However,
neither an increase in Cmax of sildenafil nor an increase in
Cmax of desmethylsildenafil correlated significantly with a
decrease in the MPAP, PAOP, MAP or P/F-ratio.
Discussion
In this study, we evaluated the effect of 50 mg of silde-
nafil administered as a single dose on pulmonary vascular
tone and oxygenation in patients with ARDS. The major
findings of the study were that sildenafil resulted in
attenuation of pulmonary arterial pressures and pulmon-
ary vascular resistance, and to a lesser degree of systemic
arterial pressures and resistance. However, the observed
profound increase in shunt fraction, as well as a marked
decrease of PaO2, may render sildenafil unsuitable for the
treatment of ARDS.
The reductions of pulmonary arterial pressures and
vascular resistance are in line with previous studies
evaluating the effect of sildenafil on ambulatory patients
with idiopathic pulmonary hypertension or pulmonary
hypertension due to lung fibrosis. However, in these
studies, reducing pulmonary hypertension was accompa-
nied by an increase in exercise capacity or elevated PaO2
[22, 23, 27]. This increase in PaO2 was explained by an
effect called preferential vasodilation in which sildenafil
is thought to selectively cause vasodilation in the lung,
emphasized by a decrease in the ratio of the pulmonary to
systemic vascular resistance index [22]. In contrast, in our
study, sildenafil decreased both pulmonary and arterial
pressure and resistance, without affecting the ratio of the
pulmonary to systemic vascular resistance index or the
ratio of the pulmonary to systemic arterial pressure. In
other words, we did not find preferential vasodilation,
which may explain the deterioration in shunt fraction and
PaO2. An explanation for these contrasting results may be
the duration of disease. Sildenafil-induced preferential
vasodilation was observed in patients with pulmonary
hypertension due to chronic pulmonary fibrosis and hence
chronic hypoxia [23]. Chronic hypoxia not only results in
vasoconstriction, but also leads to vascular remodeling
with thickening of the medial layer, eventually even
obliterating the endovascular lumen [28]. Once medial
thickening has occurred, the vasoreactivity in diseased
lung areas is restricted [29], which may allow for pref-
erential vasodilation in well-ventilated areas, thereby
decreasing the shunt fraction. In contrast, in ARDS,
duration of disease was less than 7 days. This time span
does not allow for intimal thickening to occur. In this
study, sildenafil may have resulted in general pulmonary
vasodilation, increasing blood flow through both well-
ventilated as well as hypoventilated (consolidated) areas,
thereby reducing hypoxic vasoconstriction and increasing
the shunt fraction, which in turn resulted in a lower
oxygenation. Impaired vasoreactivity in chronic pulmon-
ary hypertension as opposed to normal vasoreactivity in
acute pulmonary hypertension (i.e., ARDS) may be the
discriminating factor in the effect of sildenafil on
oxygenation.
A compromised pulmonary blood flow may have
contributed to the deterioration of oxygenation. Although
both pulmonary blood pressure and pulmonary resistance
decreased after sildenafil administration, we did not
assess the net effect of these parameters on pulmonary
blood flow. However, the clearance of CO2 was not
affected, rendering this hypothesis unlikely. Notably,
most of the patients were on vasopressor therapy, which
may have rendered these patients at increased risk of an
increasing shunt fraction after sildenafil administration.
Although the effect of sildenafil on worsening of oxy-
genation or shunt fraction was the same in patients treated
with vasopressor therapy compared to those without
vasopressors, the number of patients was too small to
draw conclusions about the applicability of sildenafil in
specific patient groups.
Right ventricular dysfunction is a common finding in
ARDS [30], contributing to prolonged mechanical venti-
lation [31] and to mortality [32]. It has been postulated
that right ventricular failure during ARDS should prompt
adjustments to ventilatory settings [33, 34], including
prone positioning [35]. As sildenafil decreased right
ventricular afterload in this study, thereby decreasing the
right ventricular stroke work index, this compound may
be an alternative strategy for ARDS patients for whom
right ventricular failure is thought to contribute to a det-
rimental course. It should be noted that we included only
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Fig. 2 Boxplot of shunt fraction during the study period displayed
as median, interquartile range (box) and range (whiskers). An
asterisk indicates statistically significant change as compared to
t = 0 (Wilcoxon signed ranks test)
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patients who strictly met the NAECC criteria for ARDS,
including a pulmonary artery occlusion wedge pressure
of \18 mmHg. It can be hypothesized that sildenafil may
benefit ARDS patients with more severe pulmonary
hypertension and concomitant higher pulmonary resis-
tance by reducing right ventricular afterload and hence
increasing right ventricular function.
In several studies with ambulatory patients, sildenafil
did not have an effect on systemic arterial blood pressure
[22, 23]. In our study, however, MAP decreased markedly
after 50 mg of sildenafil together with a reduced SVRI.
This effect may be attributed to the fact that seven out of
ten patients required vasopressor support, four because of
sepsis. During sepsis, increased NO release leads to
vasodilation [36]. Increased levels of NO may lead to
elevated levels of cGMP in the systemic circulation,
which are not being degraded because of PDE inhibition
by sildenafil. As a consequence, this may lead to more
overt vasodilation in critically ill or septic patients when
compared to ambulatory patients.
We did not find a correlation between hemodynamic
or respiratory changes and the plasma concentrations of
sildenafil or desmethylsildenafil. Although impaired gas-
tric voiding was an exclusion criterion, we cannot rule out
intestinal malabsorbtion. However, as sildenafil resulted
in distinct hemodynamic and respiratory effects, malab-
sorbtion probably did not account for the absence of a
correlation between effects and drug levels in this study.
Rather, the sample size may have been too small to
account for the great variability in pharmacodynamic
properties of drugs generally found in critically ill
patients [37, 38].
Implications of the study
Although levels of PO2 have not been associated with
adverse outcome in ARDS, it can be hypothesized that
prolonged administration of sildenafil may prolong the
need of ventilatory support when oxygenation levels are
targeted. Results of the study do not justify the use of
sildenafil to improve oxygenation. In patients in whom
right ventricular dysfunction is a therapeutic target, sil-
denafil may be of use. The effect of sildenafil on mortality
in ARDS patients with right ventricular failure, however,
remains to be determined.
Conclusion
Administration of sildenafil to patients with ARDS ame-
liorates pulmonary hypertension, thereby decreasing right
ventricular afterload, but has deleterious effects on shunt
fraction, oxygenation and systemic blood pressure. In
spite of the promising features of sildenafil found in
preclinical studies, results of this study do not justify a
routine place for sildenafil in the treatment of ARDS
patients. Whether sildenafil may be beneficial in ARDS
patients with more severe pulmonary hypertension
remains to be determined.
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